Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ZOFRAN 8 MG

ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG · DIN 02213575 · NOVARTIS PHARMACEUTICALS CANADA INC

Health Canada status: CANCELLED POST MARKET

What is ZOFRAN?

ZOFRAN 8 MG contains ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02213575, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Mar-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ZOFRAN used for?

Prevention of nausea and vomiting associated with emetogenic chemotherapy and radiotherapy; prevention and treatment of post-operative nausea and vomiting.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

What else is ZOFRAN called?

The same molecule, ONDANSETRON, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
Ondansetron BluefishLatinNorway, Sweden
DantronLatinMorocco, South Africa
Ondansetron Abacus MedicineLatinSweden
Ondansetron EbbLatinSweden
APX-OndansetronLatinAustralia
APX-Ondansetron ODTLatinAustralia
CHEMOSETLatinMorocco
Ondansetron EQL PharmaLatinSweden
Ondansetron ODT ViatrisLatinAustralia
Ondansetron ODT-DRLALatinAustralia
ONDANSETRON ODT-WGRLatinAustralia
Ondansetron SZLatinAustralia
Ondansetron SZ ODTLatinAustralia
Ondansetron Tablets ViatrisLatinAustralia
Ondansetron TevaLatinCzechia, Sweden

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02213575
Brand nameZOFRAN
Generic / active ingredientONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG
ManufacturerNOVARTIS PHARMACEUTICALS CANADA INC
Strength8 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeA04AA01 ONDANSETRON
AHFS class56:22.20
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date14-Mar-2017
Original market date1991-12-30 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02213575
DIN (unpadded, as printed on some documents)2213575
Brand nameZOFRAN
Active ingredient / INNONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG
ATC codeA04AA01
ATC anatomical main groupA — Alimentary tract and metabolism
ATC therapeutic subgroupA04
AHFS class56:22.20
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderNOVARTIS PHARMACEUTICALS CANADA INC

Health Canada approved product monograph (PDF)

How is it administered?

Adults: 8-16 mg IV or 8-16 mg orally depending on indication. Max IV dose 16 mg. Infuse IV over 15 mins. Hepatic impairment: max 8 mg/day. Follow specific guidelines for elderly to reduce cardiac risk.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in provided text snippet (refers to section 11), but mentions stability of diluted solutions for up to 2-7 days depending on conditions.

How is it supplied?

Tablets: blister packs of 10. ODT: 2 x 5 unit dose blisters. Oral Solution: 50 mL bottles. Injection: 2 mL and 4 mL ampoules in boxes of 5.

Which pack is which?

Strength on the label8 MG
Dosage formTABLET
RouteORAL
Packaging as described in the monographTablets: blister packs of 10. ODT: 2 x 5 unit dose blisters. Oral Solution: 50 mL bottles. Injection: 2 mL and 4 mL ampoules in boxes of 5.
StorageNot explicitly detailed in provided text snippet (refers to section 11), but mentions stability of diluted solutions for up to 2-7 days depending on conditions.

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.

Confirm the pack and get a price

Contraindications

Hypersensitivity to the drug or any components; concomitant use of apomorphine (due to risk of profound hypotension and loss of consciousness).

Warnings and precautions

Dose-dependent QTc prolongation; risk of Torsade de Pointes; myocardial ischemia and coronary artery spasm; serotonin syndrome; avoid in congenital long QT syndrome.

Is ONDANSETRON in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for ZOFRAN

What can be used instead?

Other Canadian products sharing ATC code A04AA01 ONDANSETRON. 59 of 135 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ACCEL-ONDANSETRON4 MGTABLETACCEL PHARMA INCMARKETEDDIN 02478927
ACCEL-ONDANSETRON8 MGTABLETACCEL PHARMA INCMARKETEDDIN 02478935
ACCEL-ONDANSETRON ODT4 MGTABLET (ORALLY DISINTEGRATING)ACCEL PHARMA INCMARKETEDDIN 02535319
ACCEL-ONDANSETRON ODT8 MGTABLET (ORALLY DISINTEGRATING)ACCEL PHARMA INCMARKETEDDIN 02535327
APO-ONDANSETRON4 MGTABLETAPOTEX INCMARKETEDDIN 02288184
APO-ONDANSETRON4 MG / 5 MLSOLUTIONAPOTEX INCMARKETEDDIN 02291967
APO-ONDANSETRON8 MGTABLETAPOTEX INCMARKETEDDIN 02288192
AURO-ONDANSETRON INJECTION2 MGSOLUTIONAURO PHARMA INCMARKETEDDIN 02491532
AURO-ONDANSETRON INJECTION2 MGSOLUTIONAURO PHARMA INCMARKETEDDIN 02491524
AURO-ONDANSETRON ODT4 MGTABLET (ORALLY DISINTEGRATING)AURO PHARMA INCMARKETEDDIN 02511282

Who else supplies ONDANSETRON worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ONDANSETRON appears in 992 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does ONDANSETRON cost around the world?

ONDANSETRON is listed on 17 national price registers Nexara tracks, across 480 pack listings published on 15 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
Australiaex-manufacturer209608 Sep 2026
SwedenAIP (pharmacy purchase price)136003 Sep 2026
United Statesacquisition66003 Sep 2026
Saudi Arabiapublic345501 Sep 2026
South Africasingle exit price434901 Sep 2026
Bahrainretail (max)153301 Sep 2026
Greeceproducer price (ex-factory)292903 Sep 2026
MoroccoPPV (public price)112905 Sep 2026
Czechiamax producer price (ex-factory)81203 Sep 2026
AustriaKVP (Kassenverkaufspreis)111103 Sep 2026
United Kingdomhospital101031 Aug 2026
United Arab Emiratespublic6831 Aug 2026
SpainPVP con IVA (public price)8805 Sep 2026
Romaniamax producer price7803 Sep 2026
Hungaryproducer price (ex-factory)5703 Sep 2026
Norwaymax AUP (pharmacy retail)3407 Sep 2026
Luxembourgreimbursement1105 Sep 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02213575. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.